180 Life Sciences Corp. — FY2022 Form 10-K
Filing identity: The request metadata names FORUM MARKETS Inc, but the supplied filing is for 180 Life Sciences Corp. (NASDAQ: ATNF; warrants: ATNFW). This summary reflects the filing text. The reporting period is the fiscal year ended December 31, 2022; this annual filing does not provide a standalone Q4 income statement.
Business context
180 Life Sciences is a clinical-stage biotechnology company developing therapeutics for chronic pain, inflammation and fibrosis through anti-TNF, synthetic cannabinoid analog (SCA), and alpha-7 nicotinic acetylcholine receptor platforms. Its lead candidate, adalimumab for early-stage Dupuytren’s Contracture, completed a Phase 2b trial. The other platforms remain preclinical; the company reported no revenue in 2022 or 2021.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $2.43 million, including related-party expense | $3.95 million, including related-party expense |
| General and administrative expense | $15.47 million, including related-party expense | $11.69 million, including related-party expense |
| Operating loss | $17.90 million | $15.64 million |
| Net loss | $38.73 million | $20.32 million |
| Cash used in operating activities | $12.13 million | $19.37 million |
| Cash provided by financing activities | $10.87 million | $25.41 million |
| Cash at year-end | $6.97 million | $8.22 million |
The company had $3.27 million of working capital at year-end, versus a $8.50 million working-capital deficit in 2021. Total liabilities were $8.31 million; loans payable were approximately $1.34 million, primarily current. Stockholders’ equity fell to $11.34 million from $39.32 million. Profit margins are not meaningful because there was no revenue.
FY2022 net loss included non-cash impairment charges of $33.55 million for goodwill and $3.34 million for in-process R&D, partly offset by a $15.14 million non-cash gain from changes in derivative-liability fair value. These items materially affected reported loss. Cash flow was also supported by approximately $12.5 million of gross proceeds from July and December 2022 equity and warrant offerings; the December offering included substantial pre-funded and common warrants.
Changes, outlook and material matters
- Research and development expense excluding related parties increased 119% year over year, while related-party R&D expense declined 92%. General and administrative expense excluding related parties rose 38%, driven mainly by legal fees and directors’ and officers’ insurance.
- The 1-for-20 reverse stock split took effect December 19, 2022. The company raised equity in July and December, and substantially increased its outstanding share count during the year.
- The Phase 2b Dupuytren’s trial reported statistically significant results for nodule hardness and ultrasound-measured size, with no related severe adverse events. The FDA questioned whether these measures would be suitable efficacy endpoints for future U.S. registration trials. No FDA marketing application had been submitted.
- Recruitment for the frozen-shoulder feasibility study ended after nine participants following a U.K. research-system request to close slow-recruiting trials; another study may be needed. Management planned a Phase 2 POCD study and was preparing a U.K. conditional marketing authorization/marketing application for Dupuytren’s disease.
- The company reported substantial doubt about its ability to continue as a going concern. It stated that cash on hand was approximately $2.7 million as of March 29, 2023 and expected it could fund operations through Q3 2023, while elsewhere warning that year-end cash was sufficient only through Q2 2023. It estimated known contractual and other cash requirements of about $10 million in 2023 and $27 million for 2024–2027, and reported monthly cash needs of approximately $900,000. Further financing is required; availability and terms are uncertain and could be dilutive.
- Material litigation includes disputes involving former KBL executives, Tyche Capital, the Bauer defendants, and D&O insurance coverage. The company’s claims and potential recoveries are uncertain; court-ordered advancement of some legal fees to a former executive may require cash outlays, and insurance reimbursement is not assured.
- Management identified a material weakness in internal control over financial reporting concerning review precision for warrant fair value and IP R&D valuation. It reported that two prior-year material weaknesses had been remediated. The auditor expressed an unqualified opinion on the financial statements but did not audit or opine on internal-control effectiveness. Management described disclosure controls as effective.
Important facts for investors to verify
- Confirm the issuer identity and whether the requested company name, FORUM MARKETS Inc, is a metadata error.
- Reconcile the stated cash runway through Q2 versus Q3 2023 and assess financing needs against operating cash burn and contractual obligations.
- Review the clinical data, FDA endpoint feedback, and the feasibility and timing of the planned U.K. marketing submission.
- Assess dilution and potential warrant overhang from 2022 offerings, including post-year-end warrant amendments and subsequent share issuances.
- Track litigation exposure, possible legal-fee advances, insurance coverage, and the status of the material weakness remediation.
- Evaluate assumptions underlying the large goodwill and IP R&D impairments and the remaining $9.06 million IP R&D carrying value.